Galapagos NV
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
05 aug 2015 - 22:26
Statutaire naam
Galapagos NV
Titel
Galapagos on track to deliver on pipeline in second half 2015
Bericht
Half-year financial results 2015
• Filgotinib shows promising efficacy and potentially differentiated safety profile in DARWIN 1 and 2 Phase 2B studies
• Phase 2 readouts expected with filgotinib: DARWIN 2 24 weeks in rheumatoid arthritis and FITZROY in Crohn's disease
• Nomination of second corrector candidate this quarter in cystic fibrosis. Initiation of Phase 1 study with GLPG2222 and Phase 2 study with GLPG1837 in Class III mutation patients expected before end 2015
• First half year financials:
o Group revenues €36.9 M
o Group net loss €34.2 M, reflecting planned increase in pipeline investment
o Half year cash of €404.6 M, including €7.2 M in restricted cash
• Full year operational cash burn guidance reiterated: €110 - €130 M, excluding alliance milestones or income from filgotinib
Datum laatste update: 28 maart 2025